

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

PA/4-30188E

APPLICATION NO.


10/728,244

APPLICANT

FUJIMOTO ET AL.

FILING DATE

DECEMBER 4, 2003

Group
1625

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
JS	AA	6,291,523	9/18/01	Fujimoto et al.			
JS	AB	6,310,099	10/30/01	Fujimoto et al.			
JS	AC	6,451,858	9/17/02	Fujimoto et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	AM					<input type="checkbox"/>	<input type="checkbox"/>
	AN					<input type="checkbox"/>	<input type="checkbox"/>
	AO					<input type="checkbox"/>	<input type="checkbox"/>
	AP					<input type="checkbox"/>	<input type="checkbox"/>
	AQ					<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	
AS	
AT	

EXAMINER

JS

DATE CONSIDERED

9/2/03

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AO	AA	3,531,493	9/29/70	Gittos et al.			
	AB	3,558,690	1/26/71	Sallmann et al.			
	AC	3,652,762	3/28/72	Sallmann et al.			
	AD	3,895,063	7/15/75	Sallman et al.			
	AE	4,173,577	11/6/79	Sallmann et al.			
	AF	4,548,952	10/22/85	Antonio V. Casas			
AO	AG	5,958,978	9/28/99	Yamazaki et al.			
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
AO	AM	DE 3445011 A1	6/13/85	Germany (and translation)			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AN	WO 94/04484	3/3/94	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 96/00716	1/11/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 97/09977	3/20/97	PCT (and translation)			<input checked="" type="checkbox"/>	<input type="checkbox"/>
AO	AQ	EP 865,788 A1	9/23/98	Europe			<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AO	AR	Sircar J.C., Curr.Opin.Invest.Drugs, Vol. 2 (4), pp. 403-407 (1993)
AO	AS	Englehardt G., Z. Rheumatol, Vol. 53, Suppl. 1, pg. 68 (1994)
AI	AT	Englehardt G., Eur. J., Clin. Pharmacology, Vol. 47 (No. 1) pg. A98 (1994)

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

As	AA	Brit. J. Pharmacol., Vol. 112, Proc. Suppl., pg. 183P (1994)
	AB	Klein T. et al., Biochemical Pharmacology, Vol. 48, No. 8, pp 1605-1610 (1994)
	AC	Mitchell J.A. et al., Proc.Natl.Acad.Sci.USA, Vol. 90, pp. 11693-11697 (1994)
	AD	Pallapies D. et al., Life Sciences, Vol. 57, No. 2, pp. 83-89 (1995)
	AE	Pairet M. et al., Proceedings of a conference, October 10-11, 1995, "Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors", Edited by John Vane et al., pp. 103-119
	AF	Seibert K. et al., Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 23, pg. 125-127 (1995)
	AG	Englehardt G., Br.J.Rheumatol. Vol. 34, Abstr. Suppl. 1, pg. 48 (1995)
	AH	Glaser K.B., Inflammopharmacology, Vol. 3, pp. 335-345, (1995)
	AI	Gierse J.K. et al., Biochem.J., Vol. 305, pp. 479-484 (1995)
	AJ	Prasit P. et al., Med.Chem.Res., Vol. 5, pp. 364-374 (1995)
	AK	Chan Chi-Chung et al., Journ.Pharmacology and Experimental Therapeutics, Vol. 274, pp. 1531-1537 (1995)
	AL	Grossman C.J. et al., Inflammation Res., Vol. 44, pp. 253-257 (1995)
	AM	Glaser K.B. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S276 (1995)
As	AN	Gamage et al., Anti-Cancer Drug Design (Vol. 7, pgs. 403-414 (1992).

EXAMINER

DATE CONSIDERED


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Grossman C.J. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S272 (1995)
AB	Warner T.D. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S274 (1995)
AC	Terlain B. et al., Presse Med., Vol. 24, No. 10, pp. 491-496 (1995)
AD	Gierse J.K. et al., Journ.Biological Chemistry, Vol. 271, No. 26, pp. 15810-15814 (1996)
AE	Englehardt G., Z. Rheumatol. Vol. 55, Suppl. 1, pg. 112 (1996)
AF	Distel M. et al., British Jour. of Rheumatology, Vol. 35 (suppl. 1) pp. 68-77 (1996)
AG	Churchill L. et al., Inflammopharmacology, Vol. 4, pp. 125-135 (1996)
AH	Steinhilber D., Pharm.Ztg., Vol. 141(37), pp. 11-18 (1996)
AI	Vane J.R. et al., Scan.J.Rheumatol. Vol. 25 (Suppl. 102) pp. 9-21 (1996)
AJ	Matsushita M. et al., Inflamm.Res., Vol. 46, pp. 461-466 (1997)
AK	Englehardt G. et al., Biochemical Pharmacology, Vol. 51, pp. 21-28 (1996)
AL	Cromlish W.A. et al., Biochemical Pharmacology, Vol. 52, pp. 1777-1785 (1996)
AM	Brideau C. et al., Inflamm.Res., Vol. 45, pp. 68-74 (1996)
AN	Moser et al., J. Med. Chem., Vol. 33, pgs. 2358-2368 (1990)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

As	AA	Patrignani P. et al., Journal of Physiology and Pharmacology, Vol. 48, 4, pp. 623-631 (1997)
	AB	Pairet M. et al., Proceedings of a conference on March 20-21, 1997, "Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential" Edited by John Vane et al., pp. 27-46
	AC	Dammann H.G. et al., Clinical Pharmacology & Therapeutics, Vol. 61, pg. 162 (1997)
	AD	Pairet M. et al., Infamm. Res., Vol. 47, Suppl. 2, pp. S93-S101 (1998)
	AE	Silvestre J. et al., Drugs of the Future, Vol. 23(6), pp. 598-601 (1998)
	AF	Giuliano F. et al., Brit. J.Pharmacol., Vol. 125, Suppl. 1, 35P (1998)
	AG	Simmons D.L. et al., Journal of Lipid Mediators, Vol. 6, pp. 113-117 (1993)
	AH	Japanese Pharmacol. Ther., Vol. 25, No. 8, pp. 2131-2136 (1997)
	AI	Japanese Journal of Inflammation, Vol. 15, No. 5, pp. 409-411 (1995)
	AJ	Cryer B. et al., Amer.J.Med., Vol. 104, No. 5, pp. 413-421 (1998)
	AK	Chemical Abstract 118:80787 (1993)
	AL	Chemical Abstracts 104: 109230 (Abstract of DE 3445011)
	AM	Griswold et al., Medicinal Research Reviews, Vol. 16, No. 2, pgs. 181-206 (1996)
	AN	

EXAMINER

[Signature]

DATE CONSIDERED

9/2/005

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.